M&A Deal Summary |
|
|---|---|
| Date | 2024-11-12 |
| Target | SciSafe |
| Sector | Life Science |
| Buyer(s) | 1315 Capital |
| Sellers(s) | BioLife Solutions |
| Deal Type | Divestiture |
| Deal Value | 73M USD |
SEARCH BY
Try For Free 7-Day Free Trial
1315 Capital is a private investment firm that provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and healthcare service companies. The Firm will consider opportunities across the US and generally looks to commit $10 to $40 million per investment. 1315 Capital was formed in 2014 and is based in Philadelphia, Pennsylvania.
| DEAL STATS | # |
|---|---|
| Overall | 21 of 21 |
| Sector (Life Science) | 6 of 6 |
| Type (Divestiture) | 3 of 3 |
| State (New Jersey) | 3 of 3 |
| Country (United States) | 19 of 19 |
| Year (2024) | 2 of 2 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-06-17 |
Primrose Bio
San Diego, California, United States Primrose Bio is a company focused on developing and licensing its manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines. Primrose Bio is based in San Diego, California. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1987 |
| Sector | Life Science |
| Employees | 409 |
| Revenue | 143M USD (2023) |
BioLife Solutions is a developer, manufacturer and supplier of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media for cells and tissues. Our proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the regenerative medicine, biobanking and drug discovery markets. Our biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death; offering commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function. BioLife Solutions was founded in 1987 and is based in Bothell, Washington.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 2 |
| State (New Jersey) | 1 of 1 |
| Country (United States) | 1 of 2 |
| Year (2024) | 1 of 2 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-08-09 |
Sexton Biotechnologies
Indianapolis, Indiana, United States Sexton Biotechnologies is a revenue-stage, biotechnology company focused on the development and sales of bioproduction tools for cell and gene therapy. Sexton develops purpose-built cell and gene therapy (CGT) tools and media to enable flexible automation and scaling of cell manufacturing processes to increase the probability of positive clinical outcomes and reduce time-to-market, failure points and labor costs. Sexton Biotechnologies Indianapolis is based in Indianapolis, Indiana. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-11-14 |
Custom Biogenic Systems
Bruce Township, Michigan, United States Custom Biogenic Systems designs and manufactures laboratory products and supplies including cryogenic freezers, isothermal freezers, and controlled rate freezers. Custom Biogenic Systems was founded in 1987 and is based in Bruce Township, Michigan. |
Sell | $6M |
